The Abirapro refers specifically to the Abirapro 250 mg product identified on this website, rather than to abiraterone as a medicine generally.
Product identity
| Characteristic | Information |
| Product | Abirapro 250 mg |
| Active ingredient | Abiraterone acetate |
| Strength | 250 mg |
| Dosage form | Tablet |
| Route | Oral |
| Therapeutic category | Antineoplastic/hormonal therapy |
| Drug class | Androgen biosynthesis inhibitor |
| Reference product | Zytiga |
| Manufacturer/marketer | Glenmark Pharmaceuticals Ltd. |
| Product-specific authorization | [Information requires verification] |
Available product information identifies Abirapro 250 mg as containing abiraterone acetate and associates the product with Glenmark Pharmaceuticals Ltd.
Reference relationship
Zytiga is the established reference product containing abiraterone acetate. Abirapro should not be described as Zytiga or as being manufactured by Janssen/Johnson & Johnson without product-specific evidence.
Therapeutic role
Abiraterone acetate inhibits CYP17A1 after conversion to active abiraterone, reducing androgen synthesis relevant to prostate cancer.
Safety
Important risks include mineralocorticoid-related hypertension, hypokalemia and fluid retention, as well as hepatotoxicity and cardiovascular concerns.
Product verification
The actual package and regulatory documentation should be checked before use.